CClinicalTrials.gg
TerminatedNCT04232189Updated Jul 23, 2021

Serum Concentrations of Pregnancy-associated Proteins for Assessment of Gestational Age Before Abortion

An observational study in Pregnancy, sponsored by Gynuity Health Projects. Terminated at 3 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2021-07-23.

Sponsored by Gynuity Health Projects · Observational

Why this study was terminated
COVID 19 related recruitment problems
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
275
Sex
Female
01

Study summary

This will be a case-series multicenter study enrolling 800 pregnant people. Serum will be collected from people seeking abortion and assayed at a qualified laboratory.

Read the detailed description

Knowledge of gestational age (GA) is essential for guiding abortion care. In 2016, Gynuity Health Projects (GHP) launched a portfolio of research that aims to explore the possibility of developing a blood or urine test for this purpose.The goal of the present study is to validate initial study findings (protocol 8000) in a larger population of people seeking abortion.

Staff will obtain a serum specimen from each participant before any cervical manipulation is performed and before any abortifacient drug is administered. The site will send the specimens to a central facility for storage until assay. Serum assays for PAPP-A and possibly other proteins will be performed at a selected laboratory by qualified experts.

02

Conditions studied

  • Pregnancy

Keywords

  • placental protein
  • gestational age
  • abortion
03

In context

Lead sponsor

Gynuity Health Projects is the lead sponsor of 112 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Pregnant people seeking abortion at multiple clinics that provide abortion through at least 18 weeks of gestation.

Inclusion criteria

  • Pregnant and seeking medical or surgical abortion
  • Has had or will have an ultrasound on the day of study enrollment or earlier during the current pregnancy
  • Able to provide blood and urine specimens before any trans-cervical procedure or mifepristone ingestion
  • Not previously enrolled in this study

Exclusion criteria

Exclusion Criteria:

  • Does not meet Inclusion Criteria
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
275 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Otherno intervention

    no intervention, just specimen collection

06

What researchers measure

Primary outcomes

  1. Negative Predictive Value 70 days

    Negative Predictive Value of Prespecified Protein Concentration in Serum for Predicting a GA of ≤70 days is \>95%

    Time frame: 1 day

  2. Negative Predictive Value 105 days

    Negative Predictive Value of Prespecified Protein Concentration in Serum for Predicting a GA of ≤105 days is \>95%

    Time frame: 1 day

07

Study locations

3 sites
  • Presidential Women's Center
    West Palm Beach, Florida 33407, United States
  • Family Planning Associates
    Chicago, Illinois 60661, United States
  • Planned Parenthood of New York City
    New York, New York 10012, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04232189
Lead sponsor
Gynuity Health Projects
Collaborators
Family Planning Associates Medical Group, LTD, Planned Parenthood of Greater New York, Presidential Women's Center
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Nov 12, 2019
Primary completion
Apr 14, 2020
Completion
Apr 14, 2020
Last update
Jul 23, 2021

Study contacts

Elizabeth G Raymond, MD
principal investigator · Gynuity Health Projects

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion